Microbix Biosystems Inc. (TSX:MBX), a Canadian life sciences stock, climbed after creating a product to help ensure the accuracy of COVID-19 disease testing
COVID-19 testing accuracy produced a healthy return for a Canadian life sciences stock Monday. Here’s some small stocks making big moves on Monday, March 30, 2020 (as of 4 pm EST):
Microbix Biosystems Inc. (TSX:MBX), a Canadian life sciences stock, gained 33% to $0.265 on Monday after announcing the creation, verification, and imminent commercial availability of a quality assessment product to help ensure the accuracy of COVID-19 disease testing.
As well, shares of HEXO Corp. (TSX:HEXO) slid 28% to $1.10 as the Canadian cannabis company said its second-quarter net revenue rose 17% to $17.0 million yet its loss from operations for the quarter ballooned to $289.4 million from a loss of $60.6 million during the same period last year.
NaiKun Wind Energy Group Inc. (TSXV:NKW), meanwhile, reported that it has entered into an agreement to sell the NaiKun Offshore Wind Farm located in the Hecate Strait off the coast of British Columbia to Northland Power in consideration for a payment based on the size of the developed Project, which is expected to equal to the majority of NaiKun’s historical development costs. Once the Project becomes operational, future payments will consist of an annual cash distribution from the Project after the operating costs and specified return on equity has been recovered by Northland. NaiKun Wind Energy stock popped 209% to $0.17 following the announcement.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Microbix Biosystems Inc. (TSX:MBX), a Canadian life sciences stock, gained 33% to $0.265 on Monday after announcing the creation, verification, and imminent commercial availability of a quality assessment product to help ensure the accuracy of COVID-19 disease testing.
, on Monday.){kind=link}